ISRCTN78348355已完成未知
A study investigating the cardioprotective benefits of remote ischaemic postconditioning in different clinical settings of myocardial ischaemia-reperfusion injury
niversity College London (UCL) (UK)0 个研究点目标入组 500 人开始时间: 2010年6月18日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Patients undergoing percutanous coronary interventions in the elective and emergecy setting and patients undergoing thrombolysis for acute myocardial infarction
- •2. Aged greater than 18 years and less than 85 years
- •3. Male and female patients
排除标准
- •1. Aged less than 18 years and greater than 85 years
- •2. Patients with severe renal impairment (estimated glomerular filtration rate [EGFR] less than 45 ml/min/1.73m2)
- •3. Patients with severe hepatic impairment
- •4. Patients with cardiac arrest in the previous 6 weeks
研究者
相似试验
已完成
不适用
Heart protection studyCoronary heart disease (CHD)Circulatory SystemChronic ischaemic heart diseaseISRCTN48489393Medical Research Council (MRC) (UK)20,000
进行中（未招募）
1 期
A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetesDiabetes Mellitus, Type 2EUCTR2015-003563-10-ROovo Nordisk A/S3,183
进行中（未招募）
1 期
A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetesDiabetes Mellitus, Type 2EUCTR2015-003563-10-ITOVO NORDISK. S.P.A.3,183
进行中（未招募）
1 期
A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetesDiabetes Mellitus, Type 2EUCTR2015-003563-10-GBovo Nordisk A/S3,183
进行中（未招募）
1 期
A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetesDiabetes Mellitus, Type 2EUCTR2015-003563-10-NLovo Nordisk A/S3,176